Advagene Biopharma Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was TWD 46.63 million compared to TWD 55.98 million a year ago. Basic loss per share from continuing operations was TWD 0.94 compared to TWD 1.13 a year ago.